Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2025-12-26 @ 3:58 AM
Study NCT ID:
NCT07118618
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-10-27
First Post:
2025-07-31
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Probenecid Administration for Alcohol Craving and Consumption
Sponsor:
Brown University
Organization:
Study Overview
Official Title:
Probenecid, Pannexin 1 Channels for Alcohol Use Disorder
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROB2
Brief Summary:
This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.
Detailed Description:
There are three aims in this study that test the hypothesis that probenecid compared to placebo, decreases:
* Aim 1 (laboratory phase): acute alcohol craving.
* Aim 2 (naturalistic phase): alcohol craving.
* Aim 3 (naturalistic phase): alcohol consumption
* Aim 1 (laboratory phase): acute alcohol craving.
* Aim 2 (naturalistic phase): alcohol craving.
* Aim 3 (naturalistic phase): alcohol consumption
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: